SCHEMBL4398975

SCHEMBL4398975

Cc1ccc2c(Cl)cnnc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
CHEK1 O14757 1/20 0.36
PARP1 P09874 1/20 0.36
PIM1 P11309 1/20 0.36
RPS6KA3 P51812 1/20 0.36
GRM2 Q14416 2/20 0.35
CYP1A2 P05177 2/20 0.35
NQO2 P16083 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ACHE P22303 4/20 0.35
PLG P00747 1/20 0.35
PLAU P00749 1/20 0.35
PLAT P00750 1/20 0.35
C1R P00736 1/20 0.35
BCHE P06276 3/20 0.34
GRIN1 Q05586 3/20 0.34
GRIN2A Q12879 3/20 0.34
ALDH1A1 P00352 3/20 0.34
HTR1A P08908 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12034335 0.85 LMNA (0.55) LMNAPARP1CYP1A2NQO2ACHE
SCHEMBL8404443 0.80 CHEK1 (0.38) LMNACHEK1PARP1PIM1RPS6KA3
SCHEMBL15028830 0.80 NR4A2 (0.40) CYP1A2KMT2AACHEBCHEALDH1A1
Hydrochloric Acid SCHEMBL15010418 0.78 NR4A2 (0.39) CYP1A2KMT2AACHEBCHEALDH1A1
SCHEMBL30462865 0.77 NT5E (0.38) CYP1A2ACHECYP2C19
SCHEMBL10739376 0.77 TRPA1 (0.40) LMNACHEK1PARP1PIM1RPS6KA3
SCHEMBL6099341 0.77 HSD17B10 (0.40) LMNAALDH1A1PDE10AKDM4EMAPT
SCHEMBL17075876 0.77 NT5E (0.38) CYP1A2ACHECYP2C19
SCHEMBL3375367 0.77 CYP1A2 (0.42) LMNACYP1A2NQO2KMT2AACHE
Hydrochloric Acid SCHEMBL6098200 0.75 CYP3A4 (0.41) LMNACYP1A2NQO2KMT2AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 WO disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 LMNA 279/4885CHEK1 4009/4885PARP1 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.